» » Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy

Download Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy fb2

by C.G. Moertel,R.J. Reitemeir
Download Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy fb2
  • Author:
    C.G. Moertel,R.J. Reitemeir
  • ISBN:
    0061417920
  • ISBN13:
    978-0061417924
  • Genre:
  • Publisher:
    Joanna Cotler Books (January 15, 1970)
  • Pages:
    253 pages
  • Language:
  • FB2 format
    1617 kb
  • ePUB format
    1570 kb
  • DJVU format
    1423 kb
  • Rating:
    4.1
  • Votes:
    698
  • Formats:
    mbr lit lrf lrf


Clinical strategy in chemotherapy of gastrointestinal cancer depends on availability of drugs with single-agent . Kovach, J. Moertel, C. Schutt, A. A controlled study of combined 1,3-bis(-ehloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.

Clinical strategy in chemotherapy of gastrointestinal cancer depends on availability of drugs with single-agent activity  . Cancer 33, 563 (1974) Scholar. 6. Lokich, J. Skarin, A. Mayer, R. Frei, . Lack of effectiveness of combined 5-fluorouracil and methyl-CCNU therapy in advanced colorectal cancer. Cancer 40, 2792 (1977) Scholar.

Moertel CG, Reitemeier RJ. 1989. Advanced Gastrointestinal Cancer - Clinical Management and Chemotherapy. Leichman L, Leichman CG, Kinzie J. et al 1985. Harper & Row, New York. Long term low dose 5-Fluorouracil (5-FU) in advanced measurable colon cancer: No correlation between toxicity and efficacy. 14. Leichman L, Fabian C, O’Bryan R. et al 1983. Evaluation of 5-FU vs a phase II drug in metastatic adenocarcinoma of the large bowel: Southwest Oncology Group (SWOG) Study 7940 (Abstract).

In: Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy. Moertel, CG, AJ Schutl, RJ Reitemeier, et al, Therapy for gastrointestinal cancer with the nitrosoureas alone and in drug combination. Cancer Treat Rep 60:729–732, 1976PubMedGoogle Scholar. New York, Harper and Row, 1970, p 192–204Google Scholar. 58. Douglass, HO, Jr, PT Levin, CG Moertel, Nitrosoureas: useful agents for treatment of advanced gastrointestinal cancer. Cancer Treat Rep 60:769–780, 1976PubMedGoogle Scholar.

Moertel, C. Reitemeier, R. Advanced gastrointestinal cancer. In: Clinical management and chemotherapy, p. 164. New York: Harper & Row 1969.

The 5-year survival rate of gastric cancer is between 8% and 9% and has not improved over the past 3 decades. In the American literature, it is reported that the application of adjuvant chemotherapy after gastric resection has led to an improvement in the survival rate.

Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy. Fluorouracil as an adjuvant to surgery in carcinoma of the colon. 102:339, 1971Google Scholar. New York, Harper and Row, 1969Google Scholar. Therapy of advanced gastrointestinal cancer with nitrosoureas. Re. :27, 1973Google Scholar. McCaughan . Keehn, . Adjuvant chemotherapy in the surgical treatment of colorectal cancer. Cancer38:1461, 1976Google Scholar.

Advanced gastrointestinal cancer Subjects. Cancer, Chemotherapy, Stomach, Intestines. There's no description for this book yet.

Advanced gastrointestinal cancer. clinical management and chemotherapy Charles G. Moertel Richard J. Reitemeier. by Charles G Moertel. Published 1969 by Harper & Row in New York.

Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival among women with locally advanced cervical cancer. Treatment of high-risk cervical cancer.

Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group.

Perioperative chemotherapy, or postoperative chemotherapy plus chemoradiation, are preferred for .

Perioperative chemotherapy, or postoperative chemotherapy plus chemoradiation, are preferred for localized gastric cancer. Because of lower toxicity, two-drug cytotoxic regimens (eg, fluoropyrimidine and oxaliplatin) are preferred for patients with advanced disease. Moertel and colleagues randomized postoperative patients with advanced gastric cancer to receive 40 Grays (Gy) of radiotherapy or 40 Gy of radiotherapy with 5-FU as a radiosensitizer and demonstrated improved survival associated with the combined-modality therapy.

Advanced Gastrointestinal cancer clinical management and chemotherapy NY, 1969, . 131. Maity . Kao . Potential molecylar targets for manipulating the radiation response. Radiation therapy of cancer of the pancreas.